Effects of sustained viral response on lipid in Hepatitis C: a systematic review and meta-analysis

• Published in: Lipids in health and disease 2024-03, Vol.23 (1), p.74-74, Article 74
• Main Authors: Mei, Tingting, Huang, Xiaojie, Tang, Shan, Liu, Menglu, Zhang, Wenyan, Yu, Haibin
• Format: Article
• Language: English
• Subjects: Antiviral agents; Antiviral Agents - therapeutic use; Blood lipids; Cholesterol; Direct-acting Antiviral agents; Drug therapy; Health aspects; Hepacivirus - genetics; Hepatitis C; Hepatitis C - drug therapy; Hepatitis C, Chronic - drug therapy; High density lipoprotein; Humans; Hyperlipidemia; Infections; Interferon; Lipid; Lipids; Lipoproteins; Liver cancer; Liver cirrhosis; Low density lipoprotein; Meta-analysis; Metabolic disorders; Patients; Physiological aspects; Review; Serum lipids; Statistical analysis; Sustained viral response
• ISSN: 1476-511X; 1476-511X
• DOI: 10.1186/s12944-023-01957-2

Direct-acting Antiviral Agents (DAAs) influence serum lipids of patients with Hepatitis C virus (HCV). This paper presents an analysis of the relevant literature to investigate the effects of DAAs in treating hepatitis C to achieve a sustained viral response (SVR) on lipid parameters. PubMed,Web of science, Embase and Central databases were searched, with a deadline of September 2023. Studies on the effects of sustained viral response on lipid parameters after DAAs treatment for hepatitis C were selected. The required information was extracted from the included studies, and then the Stata 12.0 was used to analyze the data quantitatively. Of 32 studies, the results showed that total cholesterol (TC) levels increased from the end of treatment (WMD = 20.144, 95%CI = 3.404, 36.884,P = 0.018) to one year after treatment (WMD = 24.900, 95%CI = 13.669, 36.131, P < 0.001). From the end of treatment (WMD = 17.728, 95%CI = 4.375, 31.082, P = 0.009) to one year after treatment (WMD = 18.528, 95%CI = 7.622, 29.433, P < 0.001), the levels of low-density lipoprotein (LDL) were also increased. High-density lipoprotein (HDL) levels were elevated from 4 weeks after treatment (WMD = 6.665, 95%CI = 3.906, 9.424, P < 0.001) to 24 weeks after treatment (WMD = 3.159,95% CI = 0.176, 6.142, P = 0.038). Triglyceride (TG) levels showed no significant change after the treatment. Hepatitis C patients who achieved SVR on DAAs showed the increase of lipid levels and the improvement of hepatic inflammation indicators AST and ALT. This may provide evidence-based medical evidence for the follow-up and monitoring of blood lipids and hyperlipidemia treatment. PROSPERO CRD42020180793.